Nivolumab,Relatlimab
bms
['melanoma']
reminder: this is an exploratory analysis. important factors: pd-l1, lag-3+, age, acral histology, m1a/b vs c, low ldh. notably, no real differences in braf mutant vs wt. #melanoma #asco22 
Melanoma+Cell Therapy Oncologist @MSKCancerCenter| Cornell/DukeMed/ MGH IM/MSKCC Onc alum | FCOI: https://t.co/kwtet64Pe4